Windlas Biotech Ltd's Q4FY25 Quarter Results
- 23 May 2025
Result Summary
- Windlas Biotech Ltd reported a 11.8% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a growth of 22.8%.
- Its expenses for the quarter were down by 14.4% QoQ and up 19.6% YoY.
- The net profit increased 9.1% QoQ and increased 48.5% YoY.
- The earnings per share (EPS) of Windlas Biotech Ltd stood at 8.1 during Q4FY25.
Financial Statments for Q4FY25
| (₹ crores) | Q4FY25 | Q3FY25 | Q4FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 175.72 | 199.13 | 143.05 | -11.8% | 22.8% |
Total Expenses | 153.10 | 178.79 | 128.00 | -14.4% | 19.6% |
Profit Before Tax | 22.63 | 20.34 | 15.04 | 11.3% | 50.5% |
Tax | 5.64 | 4.76 | 3.60 | 18.5% | 56.7% |
Profit After Tax | 16.99 | 15.58 | 11.44 | 9.1% | 48.5% |
Earnings Per Share | 8.10 | 7.40 | 5.40 | 9.5% | 50.0% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Windlas Biotech Ltd is a prominent player in the pharmaceutical industry, primarily engaged in the manufacturing and development of pharmaceutical formulations. The company focuses on producing a wide range of products, including generic medications, complex generics, and various health supplements. Windlas Biotech is known for its robust contract manufacturing services, catering to domestic markets as well as international clients. The company's expertise lies in leveraging advanced technology and research capabilities to deliver high-quality pharmaceutical solutions. As of the latest data, there are no specific recent developments or major changes reported for the company.
Revenue
In the fourth quarter of fiscal year 2025 (Q4FY25), Windlas Biotech Ltd reported a total income of ₹175.72 crores. This represents a decline of 11.8% compared to the previous quarter (Q3FY25), where the total income stood at ₹199.13 crores. However, on a year-over-year basis, there was a significant increase of 22.8% from the same quarter in the previous fiscal year (Q4FY24), when the total income was ₹143.05 crores. This indicates a substantial growth in revenue over the year, despite the quarter-over-quarter decline.
Profitability
The financial performance of Windlas Biotech Ltd in Q4FY25 highlights a profit before tax of ₹22.63 crores, an 11.3% increase from the previous quarter's ₹20.34 crores. Year-over-year, the profit before tax rose by 50.5% from ₹15.04 crores in Q4FY24. The tax expense for Q4FY25 was ₹5.64 crores, representing an 18.5% increase from Q3FY25 and a 56.7% increase from Q4FY24. Consequently, the profit after tax for Q4FY25 amounted to ₹16.99 crores, which is a 9.1% increase from Q3FY25 and a 48.5% increase from Q4FY24. These figures reflect a strong profitability trajectory for the company.
Operating Metrics
The operating expenses for Windlas Biotech Ltd in Q4FY25 totaled ₹153.10 crores, marking a decrease of 14.4% from the previous quarter's expenses of ₹178.79 crores. Compared to the same quarter in the previous fiscal year, operating expenses increased by 19.6% from ₹128.00 crores. The earnings per share (EPS) for Q4FY25 was ₹8.10, showing a 9.5% increase from the previous quarter's EPS of ₹7.40 and a 50.0% increase from Q4FY24's EPS of ₹5.40. These operating metrics indicate a reduction in quarterly expenses and enhanced earnings efficiency over the year.